Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Use of Diagnostic Measures (Including Blood Eosinophil Counts) and Their Impact on Lung Specialists' Treatment Decisions in Patients With COPD in Germany
NCT number | NCT03465332 |
Other study ID # | 207733 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 19, 2018 |
Est. completion date | August 30, 2018 |
Verified date | January 2019 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will evaluate the diagnostic measures (including blood eosinophil counts) commonly used by lung specialist's in routine clinical care of subjects with COPD in Germany and how these diagnostic tests influence the physician's treatment decisions. The study will be conducted in three parts. In the first part, lung specialist's, who will not participate in the survey, will develop doctor's questionnaire. The second part is an interventional cross-sectional study, wherein approximately 30 lung specialists will be enrolled and data on their perspective on diagnosis and treatment of COPD subjects will be collected via the revised doctor's questionnaire. The third part is a retrospective non-interventional study where each doctor will collect retrospective data from selected subjects with COPD from the time of informed consent up to 12 months before. The retrospective data will be collected from subject files of approximately 250 subjects with COPD.
Status | Completed |
Enrollment | 251 |
Est. completion date | August 30, 2018 |
Est. primary completion date | August 30, 2018 |
Accepts healthy volunteers | |
Gender | All |
Age group | 35 Years and older |
Eligibility |
Inclusion Criteria: For participating centers (Sample 1: 30 lung specialists from Germany) - More than 10 years of experience in respiratory medicine - At least 500 subjects under supervision in hospital- or office-based setting: a) Focus on obstructive lung diseases. b) Board certification. c) Informed consent to participate in this study and to share files of consenting subjects. For subjects (Sample 2: 250 COPD subjects from these 30 doctors from sample 1) - Written informed consent to use his/her data. - Age >=40 years - Pack years >10, current or former smoking - Duration of COPD: >=1 year since COPD diagnosis record in subject files (also confirmed by spirometry) - No concurrent asthma diagnosis - At least one year of documented disease history at participating study doctors and have to be under the care of the before mentioned physician during this time because of COPD. Exclusion Criteria: - Subjects who are pregnant and breastfeeding (in the last 12 months) - Subjects currently participating in any interventional study - Subjects with severe comorbidities which would have influence on the COPD therapy |
Country | Name | City | State |
---|---|---|---|
Germany | GSK Investigational Site | Beelitz | Brandenburg |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Bruchsal | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Cottbus | Brandenburg |
Germany | GSK Investigational Site | Frankfurt | Hessen |
Germany | GSK Investigational Site | Fuerstenwalde | Brandenburg |
Germany | GSK Investigational Site | Garmisch-Partenirchen | Bayern |
Germany | GSK Investigational Site | Guetersloh | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Halberstadt | Sachsen-Anhalt |
Germany | GSK Investigational Site | Halle | Sachsen-Anhalt |
Germany | GSK Investigational Site | Hettstedt | Sachsen-Anhalt |
Germany | GSK Investigational Site | Koblenz | Rheinland-Pfalz |
Germany | GSK Investigational Site | Kyritz | Brandenburg |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Leipzig | Sachsen |
Germany | GSK Investigational Site | Lutherstadt Wittenberg | Sachsen-Anhalt |
Germany | GSK Investigational Site | Menden | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Nuernberg | Bayern |
Germany | GSK Investigational Site | Potsdam | Brandenburg |
Germany | GSK Investigational Site | Rostock | Mecklenburg-Vorpommern |
Germany | GSK Investigational Site | Schleswig | Schleswig-Holstein |
Germany | GSK Investigational Site | Ulm | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Warendorf | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Wiesbaden | Hessen |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline | Institut Dr. Schauerte (IDS) |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of physicians with usage of diagnostic tests in routine clinical practice | The data on diagnostic test including blood eosinophil count commonly used by lung specialists in routine clinical practice will be obtained from doctor's questionnaire. | Up to 12 months | |
Primary | Number of physician reported rationale for choice of diagnostic test | The reasons for choice of diagnostic test will be determined from doctor's questionnaires and from medical chart review. | Up to 12 months | |
Secondary | Number of physician reported reasons for blood eosinophil test selection | The reasons blood eosinophil test selection will be analyzed using data from doctor's questionnaires. | Up to 12 months | |
Secondary | Number of physician reported reasons for drug selection | The selection of drugs by lung specialists for subjects with COPD will be analyzed using information obtained from medical chart review. | Up to 12 months | |
Secondary | Number of subjects with use of other diagnostic measures | Number of subjects with use of other diagnostic measures such as spirometry, X-ray, thoracic computer tomography and specific blood tests will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with use of patient reported outcome (PRO) assessment | Number of subjects with use of questionnaires like COPD assessment test (CAT) and dyspnea assessment will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with a history of respiratory medication | Number of subjects with a history of respiratory medication will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects receiving current medication | Number of subjects receiving current medication will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects receiving COPD maintenance treatment | Number of subjects receiving COPD maintenance treatment will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects receiving immunosuppressive treatment | Number of subjects receiving immunosuppressive treatment will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects receiving allergic treatment | Number of subjects receiving allergic treatment will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects receiving oral corticosteroids (OCS) for exacerbations | Number of subjects with maintenance and rescue use of OCS for exacerbations will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with use of antibiotics | Number of subjects with use of antibiotics will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects receiving any COPD medication | Number of subjects receiving any COPD medication will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with history of exacerbations | Number of subjects with history of exacerbations will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with hospitalization for COPD | Number of subjects with hospitalization for COPD will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with emergency room visits related to COPD | Number of subjects with emergency room visits related to COPD will be analyzed using data from subject files. | Up to 12 months | |
Secondary | Number of subjects with concomitant diseases | Number of subjects with concomitant diseases will be analyzed using data from subject files. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|